Radiopharmaceuticals Development Lab, RDL
- Chemistry -
02 Research
A. Nanoparticle agents
i. Practical development of
nanoparticle for clinical use by enhancement of hydrophilicity and introduction
of multi-functional groups using amphiphile encapsulation method.
ii. Development of multimodal
imaging agents for PET-MRI or PET-fluorescence.
B. Tumor imaging agents
i. Development of nitroimidazole
derivatives for hypoxia imaging.
ii. Development of PSMA target tumor
imaging agents for prostate cancer.
iii. Development
of amino acid derivatives.
C. Brain imaging agents
i. Development of brain receptor imaging
agents: mGluR, benzodiazepine(GABA) receptor.
ii. Development of serotonergic and dopaminergic system imaging agents.
iii. Development of brain perfusion
imaging agents.
iv. Development
of beta-amyloid plaque imaging agents: benzylideneaniline and benzothiophene.
D. Etc.
i. Radiolabeling methodology
i. Development of glomerular
filtration imaging agents.
ii. Development of albumin based
radiopharmceuticals for lymphoscintigraphy or atherosclerosis imaging: LSA,
MSA.
iv. Development of therapeutic
radiopharmaceuticals: Re-188, Lu-177, Y-90, I-131 etc.